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Hyperglycemia modulates extracellular amyloid-β
concentrations and neuronal activity in vivo
Shannon L. Macauley,1 Molly Stanley,1 Emily E. Caesar,1 Steven A. Yamada,1 Marcus E. Raichle,1,2 Ronaldo Perez,1
Thomas E. Mahan,1 Courtney L. Sutphen,1 and David M. Holtzman1
Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, and 2Department of Radiology, Washington University School of Medicine,

1

St. Louis, Missouri, USA.

Epidemiological studies show that patients with type 2 diabetes (T2DM) and individuals with a diabetes-independent
elevation in blood glucose have an increased risk for developing dementia, specifically dementia due to Alzheimer’s disease
(AD). These observations suggest that abnormal glucose metabolism likely plays a role in some aspects of AD pathogenesis,
leading us to investigate the link between aberrant glucose metabolism, T2DM, and AD in murine models. Here, we
combined two techniques — glucose clamps and in vivo microdialysis — as a means to dynamically modulate blood glucose
levels in awake, freely moving mice while measuring real-time changes in amyloid-β (Aβ), glucose, and lactate within the
hippocampal interstitial fluid (ISF). In a murine model of AD, induction of acute hyperglycemia in young animals increased
ISF Aβ production and ISF lactate, which serves as a marker of neuronal activity. These effects were exacerbated in aged AD
mice with marked Aβ plaque pathology. Inward rectifying, ATP-sensitive potassium (KATP) channels mediated the response to
elevated glucose levels, as pharmacological manipulation of KATP channels in the hippocampus altered both ISF Aβ levels and
neuronal activity. Taken together, these results suggest that KATP channel activation mediates the response of hippocampal
neurons to hyperglycemia by coupling metabolism with neuronal activity and ISF Aβ levels.

Introduction

The aggregation and subsequent cerebral accumulation of the
amyloid-β (Aβ) peptide is a key initiating factor in Alzheimer’s disease (AD), where Aβ aggregation begins approximately 15 years prior
to the onset of cognitive symptoms (1, 2). In addition to extracellular
Aβ aggregation and subsequently intraneuronal tau accumulation,
decreased glucose metabolism also occurs in regions prone to AD
pathology during this presymptomatic period. Although both Aβ
and tau are central to AD pathogenesis, it is unclear whether glucose dysregulation is an initiator of AD pathology, a secondary consequence of neuronal dysfunction due to Aβ and tau deposition, or
both. Recent epidemiological studies demonstrate that individuals
with type 2 diabetes (T2DM) are 2–4 times more likely to develop
AD (3–5), individuals with elevated blood glucose levels are at an
increased risk to develop dementia (5), and those with elevated
blood glucose levels have a more rapid conversion from mild cognitive impairment (MCI) to AD (6), suggesting that disrupted glucose homeostasis could play a more causal role in AD pathogenesis.
Although several prominent features of T2DM, including increased
insulin resistance and decreased insulin production, are at the forefront of AD research (7–10), questions regarding the effects of elevated blood glucose independent of insulin resistance on AD pathology
remain largely unexplored. In order to investigate the potential role
of glucose metabolism in AD, we combined glucose clamps and in
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vivo microdialysis as a method to measure changes in brain metabolites in awake, freely moving mice during a hyperglycemic challenge.
Our findings suggest that acute hyperglycemia raises interstitial
fluid (ISF) Aβ levels by altering neuronal activity, which increases
Aβ production. Since cerebral glucose metabolism is tightly linked
to neuronal activity (11, 12) and elevated neuronal activity increases
Aβ production (13–15), we explored the role of inward rectifying,
ATP-sensitive potassium (KATP) channels as one mechanism linking glucose metabolism, neuronal excitability, and ISF Aβ. Our data
suggests that KATP channels can mediate the response of hippocampal neurons to elevated blood glucose levels by coupling changes in
metabolism with neuronal activity and ISF Aβ.

Results and Discussion

The levels of soluble, monomeric Aβ in the brain determine the
likelihood that Aβ will aggregate and lead to toxicity (13, 16).
Therefore, we first sought to assess the acute effects of hyperglycemia on the concentration of Aβ within the brain ISF. We coupled
glucose clamps (17) with in vivo microdialysis (18) in APPswe/
PS1ΔE9 (APP/PS1) mice that were 3 months old, an age prior to
the onset of brain Aβ deposition (19). These techniques allowed
us to acutely manipulate systemic blood glucose levels in awake,
freely moving mice while simultaneously assessing dynamic
changes in brain metabolites in hippocampal ISF. During a 4-hour
glucose clamp, blood glucose levels were raised from 93.8 ± 8.2
mg/dl to 204.2 ± 4.5 mg/dl, representing a 2.2-fold increase from
baseline in 3-month-old APP/PS1 mice (Figure 1A). A comparable
effect was seen in WT mice receiving the same metabolic challenge (Supplemental Figure 1; supplemental material available
online with this article; doi:10.1172/JCI79742DS1). This elevation
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Figure 1. Hyperglycemia increases ISF
glucose and Aβ levels in the APP/PS1 hippocampus in vivo. (A) Blood glucose levels
in 3-month-old APP/PS1 mice (n = 6–8 mice/
group) during fasted baseline and hyperglycemic clamp. (B) ISF glucose levels increased
from 0.158 ± 0.004 to 0.306 ± 0.011 mmol/l
during hyperglycemia in 3-month-old APP/
PS1 mice (n = 6–8 mice/group). (C) Hyperglycemia increased ISF Aβ levels by 24.5% ±
3.8% in 3-month-old APP/PS1 mice during
and after clamp (n = 6–7 mice/group). (D) ISF
Aβ correlates with ISF glucose during hyperglycemia (n = 6 mice, Pearson’s r = 0.6032;
P < 0.01). (E) ISF glucose levels increased
from 0.153 ± 0.003 to 0.397 ± 0.0149 mmol/l
during hyperglycemia in 18-month-old APP/
PS1 mice (n = 6–7 mice/group). (F) Hyperglycemia increased ISF Aβ levels by 38.8% ±
5.3% in 18-month-old APP/PS1 mice, during
and after glucose clamps (n = 6–7 mice/
group). (G) Hyperglycemia increases ISF
lactate, a marker of neuronal activity (n = 7
mice/group). (H) Compound E decreases ISF
Aβ during hyperglycemia and does not alter
ISF Aβ half-life, demonstrating hyperglycemia alters Aβ production, not Aβ clearance.
Data represent mean ± SEM. Significance
denoted *P < 0.05, **P < 0.01, and
***P < 0.001 using 2-way ANOVA (C and F)
or Student’s t tests (A, B, E, G, and H).
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Figure 2. Modulation of hippocampal KATP channels
affects ISF Aβ and lactate in vivo. (A) Glibenclamide, a KATP antagonist, was given via reverse
microdialysis and increased ISF Aβ in a dosedependent manner, with a maximal increase of
36.2% ± 3.2% at 100 μM. The left panel represents
a time course of the 100 μM dose, while the right
demonstrates the dose-dependent effects of
glibenclamide. (B) ISF lactate increased in a dosedependent manner, with a maximal increase of
73.3-5% ± 19.8%. The left panel represents a time
course of the 100 μM dose, while the right illustrates the dose-dependent effects of glibenclamide.
(C) Diazoxide, a KATP agonist, did not alter ISF Aβ
levels. The left panel demonstrates a time course
of the 300 μM dose of diazoxide, where the right
shows that diazoxide does not affect ISF Aβ at any
dose. (D) Diazoxide (300 μM) decreased ISF lactate
by 22.5% ± 4.3% after administration. The left
panel demonstrates the time course of the
300 μM dose of diazoxide, while the right shows a
dose response of diazoxide. Data represent mean
± SEM. For all analyses, n = 5–7 mice/group per
glibenclamide dose and n = 4–5 mice/group per
diazoxide dose. *P < 0.05, **P < 0.01, ***P < 0.001
using a 1-way ANOVA.

in blood glucose resulted in a 1.9-fold increase in hippocampal
ISF glucose (Figure 1B). ISF Aβ increased by 24.5% ± 3.8% during
the hyperglycemia challenge, an effect that was sustained after
euglycemia was restored subsequent to the glucose clamp (Figure 1C). While the effects of glucose on ISF Aβ were variable, ISF
glucose correlated with ISF Aβ during hyperglycemia (Pearson’s
r = 0.6032; P < 0.01), demonstrating that hippocampal Aβ concentrations are likely modulated by blood glucose levels (Figure 1D).
Hypothesizing that the presence of Aβ aggregation into amyloid plaques and oligomers promotes localized injury and affects
the brain’s response to hyperglycemia, we altered blood glucose
levels in mice with significant Aβ plaque burden (Supplemental Figure 2). Using the same approach in 18-month-old APP/

PS1 mice where blood glucose was clamped
between 150–200 mg/dl, increases in blood
glucose raised ISF glucose 2.6-fold from baseline (Figure 1E). Hyperglycemia significantly
increased hippocampal ISF Aβ by 38.8% ±
5.3%, with a maximal effect of 45.6% ± 9.0%,
which persisted after euglycemia was restored
(Figure 1F). The hyperglycemia-dependent
increase in ISF Aβ levels was 1.6-fold higher in
18-month-old mice compared with 3-monthold mice, demonstrating that older mice with
significant plaque pathology respond differentially to a hyperglycemic insult. Previous
studies demonstrated that increased synaptic
activity drives Aβ release from an endocytic
pool in vivo, resulting in an increase in ISF Aβ
but not total tissue Aβ (14, 15, 18). We found
that hyperglycemia increased ISF Aβ specifically, while the total amount of Aβ40 and Aβ42
within the brain did not change (Supplemental
Figure 3). Due to the astrocyte neuron lactate shuttle, extracellular
lactate can be used as a marker of neuronal activity, and previous
work shows that it increases in concert with ISF Aβ (13, 20–22). ISF
lactate increased during glucose clamps, suggesting hyperglycemia increases both neuronal activity and ISF Aβ (Figure 1G and
Supplemental Figure 4). To determine whether elevations in ISF
Aβ were due to increased production or decreased clearance of Aβ,
we administered compound E, a potent gamma secretase inhibitor, concurrently with hyperglycemia as a means to abolish Aβ production and to measure the rate of ISF Aβ clearance. This showed
that the rate of ISF Aβ clearance did not differ in the presence versus the absence of hyperglycemia, illustrating that the hyperglycemia-induced increase in ISF Aβ levels is not due to a significant
jci.org   Volume 125   Number 6   June 2015
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Figure 3. Pharmacological manipulation of KATP channels blocks
hyperglycemia-induced increases
in ISF Aβ. (A) In 18-month-old
APP/PS1 mice, glucose clamps
increase ISF Aβ. However, when
diazoxide, a KATP agonist, is given
via reverse microdialysis during hyperglycemia, the increase
in ISF Aβ is blocked (38.84% ±
3.5% vs. 9.33% ± 2.1% increase).
(B) Treatment with diazoxide
decreased hippocampal ISF lactate
in 18-month-old APP/PS1 mouse
brains during hyperglycemia,
suggesting decreased neuronal
activity coincides with decreased
ISF Aβ (11.8% ± 3.6% vs. –4.043%
± 3.4%). Data represent mean
± SEM. For all analyses, n = 6–7
mice/group, *P < 0.05, ***P <
0.001 using 2-way ANOVA.

slowing of Aβ clearance (Figure 1H). Since both T2DM and AD are
diseases of aging and Aβ deposition begins about 15 years prior to
the onset of dementia due to AD, these findings suggest that poor
glycemic control during a presymptomatic period could increase
basal neuronal activity, drive Aβ production/release, and instigate
or exacerbate Aβ deposition.
Elevated extracellular glucose levels can evoke rapid changes
in neuronal excitability through KATP channels (23, 24). KATP channels are hetero-octameric proteins composed of 4 inner poreforming subunits (Kir6.1 or Kir6.2) and 4 sulfonylurea receptor
(SUR) subunits. Increased glucose concentrations lead to elevations in intracellular ATP, causing KATP channel closure, membrane depolarization, and increased cellular excitability. Although
best described for their role in insulin secretion in pancreatic β
cells, KATP channels are found on both neurons and astrocytes (25)
and can couple cellular metabolism with neuronal activity. To
investigate the role of KATP channel activity on glucose-dependent
increases in ISF Aβ, we pharmacologically manipulated hippocampal KATP channels under euglycemic and hyperglycemic conditions. We delivered glibenclamide, a KATP channel antagonist,
to the APP/PS1 hippocampus via reverse microdialysis and found
that it increased ISF Aβ and lactate levels in a dose-dependent
manner, with a maximal effect of 36.2% ± 3.2% and 73.3% ± 19.8%,
respectively (Figure 2, A and B). These findings illustrate that closure of KATP channels leads to both increased neuronal activity and
extracellular concentrations of Aβ (Figure 2, A andB). Conversely,
we investigated whether the KATP channel agonists, diazoxide and
pinacidil, affect ISF Aβ and lactate levels by opening KATP channels
2466
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and hyperpolarizing cells (Figure 2, C and D, and Supplemental
Figure 5). Although no overall change in ISF Aβ was observed (Figure 2C and Supplemental Figure 5A), diazoxide decreased ISF lactate by 22.5% ± 4.3%, suggesting an inhibitory effect on neuronal
activity (Figure 2D). This finding is consistent with previous work,
demonstrating that diazoxide decreased action-potential frequency and calcium influx in cultured cortical neurons (26). Together,
our findings suggest that KATP channels alter cellular excitability
within the hippocampus and that increased cellular excitability via
KATP channel activation leads to increased ISF Aβ.
To determine whether increases in ISF Aβ during hyperglycemia were due to KATP channels, we investigated whether opening
KATP channels prevented increases in ISF Aβ during hyperglycemia.
Diazoxide was infused into the hippocampus via reverse microdialysis prior to and during hyperglycemia in 18-month-old APP/PS1
mice. ISF Aβ levels did not significantly change prior to and during
hyperglycemia in the presence of diazoxide (Figure 3A). In contrast,
hyperglycemia alone resulted in a 38.8% ± 5.3% elevation in ISF Aβ,
demonstrating that diazoxide blocks the increase in ISF Aβ during
hyperglycemia (Figure 3A). Using ISF lactate levels as a measure of
neuronal activity, diazoxide treatment blocked the hyperglycemiadependent increase in ISF lactate levels (Figure 3B). Taken together,
these findings demonstrate that KATP channel activation mediates
the response of hippocampal neurons to elevated glucose levels by
coupling metabolism with neuronal activity and ISF Aβ.
By combining glucose clamps with in vivo microdialysis,
we were able to modulate blood glucose levels in awake, freely moving APP/PS1 mice while simultaneously investigating
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changes in Aβ, glucose, and lactate within the hippocampal ISF.
Our data demonstrate that elevated blood glucose levels affect
hippocampal metabolism, neuronal activity, and ISF Aβ concentrations in young mice, lacking any appreciable Aβ plaque load.
However, in aged mice with marked Aβ deposition, the effect
of hyperglycemia on ISF Aβ is exacerbated, suggesting that ageor pathology-dependent changes result in an alteration of the
brain’s response to a metabolic insult. Since extracellular Aβ,
and subsequently tau, aggregate in a concentration-dependent
manner during the preclinical period of AD while individuals
are cognitively normal (27), our findings suggest that repeated
episodes of transient hyperglycemia, such as those found in
T2DM, could both initiate and accelerate plaque accumulation.
Thus, the correlation between hyperglycemia and increased ISF
Aβ provides one potential explanation for the increased risk of
AD and dementia in T2DM patients or individuals with elevated
blood glucose levels. In addition, our work suggests that KATP
channels within the hippocampus act as metabolic sensors and
couple alterations in glucose concentrations with changes in
electrical activity and extracellular Aβ levels. Not only does this
offer one mechanistic explanation for the epidemiological link
between T2DM and AD, but it also provides a potential therapeutic target for AD. Given that FDA-approved drugs already
exist for the modulation of KATP channels and previous work
demonstrates the benefits of sulfonylureas for treating animal
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